Recent Updates
Recently added Catalysts
BNTX Negative Sentiment Score: 25/100

BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been initiated against BioNTech SE, with allegations of materially false and misleading statements made during the Class Period from March 30, 2022, to October 13, 2023. The complaint claims that BioNTech overinflated demand for its COVID-19 vaccine Comirnaty and failed to disclose excess inventory of raw materials. As a result, the company faces potential financial implications, including significant inventory write-offs. Investors are encouraged to take action before the March 12, 2024 deadline to participate in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against BioNTech for misleading investors.
  • The complaint alleges BioNTech overstated demand for its vaccine Comirnaty.
  • There are claims of excess inventory of raw materials and vaccine doses leading to potential financial losses.
  • The company's public statements are accused of being materially false and misleading.

Full Press Release Details

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired BioNTech securities between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class Period”). Investors have until March 12, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) BioNTech overstated demand for Comirnaty and/or its commercial prospects; (ii) the Company and/or Pfizer had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (iii) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (iv) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
If you purchased or otherwise acquired BioNTech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the class action lawsuit against BioNTech about?

The lawsuit claims BioNTech made false statements about its business and operations.

What is the time frame for the BioNTech class action?

The Class Period for the lawsuit is from March 30, 2022, to October 13, 2023.

How can I participate in the BioNTech lawsuit?

Investors can apply to be lead plaintiffs until March 12, 2024.

Who can I contact for more information on the lawsuit?

Contact Brandon Walker or Marion Passmore at investigations@bespc.com.

What did BioNTech allegedly misrepresent?

BioNTech allegedly overstated demand for its vaccine and had excess inventory.

Last updated: Mar 9, 2024